Further studies reported that pharmacological inhibition of Mstn directly or by decoy receptors improves bone integrity and/or muscle loss in mouse models of osteoarthritis, rheumatoid arthritis, osteogenesis imperfecta and diabetes [21, 42–44]. Here, MSTN is linked to osteogenesis imperfecta.